Crescent Biopharma, Inc. Common Stock (CBIO) Stock
Key stats
- Market cap
- $548.10M
- Price / Earnings ratio
- -3.1x
- EPS (TTM)
- -$7.63
- Volume
- Loading
- 52-week high
- $27.41
- 52-week low
- $8.72
Source: third-party data provider, as of November 13, 2026
Compare with CBIO
Recent news
No recent news
Technical indicators
- RSI 14
- 57.54
- MACD 12/26/9
- -0.13
- EMA 9 of MACD
- -0.39
- MACD histogram
- 0.26
- SMA 50
- $15.01
- Price below SMA 50
- EMA 50
- $14.49
- Price above EMA 50
- SMA 200
- $15.91
- Price below SMA 200
- EMA 200
- $15.11
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
About Crescent Biopharma, Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Joshua T. Brumm | CEO & Director | 1978 |
| Dr. Jonathan McNeill M.D. | President & COO | 1985 |
| Mr. Richard William Scalzo M.B.A. | Chief Financial Officer | 1986 |
| Dr. Ellie Im M.D. | Chief Medical Officer | 1978 |
| Mr. Ryan Lynch | Senior VP of Finance, Treasurer & Chief Accounting Officer | 1984 |
| Dr. Wenjie Cheng Ph.D. | Senior Vice President of Technical Operations | — |
| Dr. Jan Pinkas Ph.D. | Chief Scientific Officer | 1969 |
| Ms. Barbara Bispham Hale J.D. | General Counsel & Corporate Secretary | 1987 |
| Ms. Amy Reilly | Chief Communications Officer | 1974 |
| Mr. Christopher Doughty | Chief Business Officer | 1988 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 57.54
- MACD 12/26/9
- -0.13
- EMA 9 of MACD
- -0.39
- MACD histogram
- 0.26
- SMA 50
- $15.01
- Price below SMA 50
- EMA 50
- $14.49
- Price above EMA 50
- SMA 200
- $15.91
- Price below SMA 200
- EMA 200
- $15.11
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $27.00
- Average
- $31.50
- High
- $36.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.8 | +11.6 | -18.6 | -5.5 | +7.8 |



